![]() |
市場調查報告書
商品編碼
2083651
數位乳房斷層合成市場:按組件、安裝類型、所有權模式、應用和最終用戶分類-2026-2032年全球市場預測Digital Breast Tomosynthesis Market by Component, Installation, Ownership Model, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,數位乳房斷層合成市場將成長至 137.7 億美元,複合年成長率為 15.27%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 50.9億美元 |
| 預計年份:2026年 | 58.1億美元 |
| 預測年份 2032 | 137.7億美元 |
| 複合年成長率 (%) | 15.27% |
數位乳房斷層合成(DBT),也稱為3D乳房乳房X光攝影,正在從一種先進的篩檢工具轉變為許多高所得醫療系統中乳房攝影影像的核心技術。此技術可擷取多張低劑量投影影像,並將其重建為薄層影像,與傳統的2D乳房X光乳房X光攝影相比,能夠幫助放射科醫師更清晰地評估重疊的乳房組織,尤其適用於乳房組織緻密的女性。
多種因素正在重塑數位乳房斷層合成(DBT)的市場環境,包括早期篩檢的建議、乳癌發生率的上升、放射科醫生的短缺以及醫院對提高診斷準確性的需求。在美國,美國預防服務工作小組(USPSTF)2024年建議40至74歲的女性每兩年進行一次乳癌篩檢,這將提高篩檢的可及性。同時,其他臨床機構繼續強調個人化風險評估、乳房密度和家族病史的重要性。
人工智慧 (AI) 正在對數位乳房斷層合成 (DBT) 的各個領域產生累積影響,包括篩檢、分流、病灶檢測、乳房密度評估、品管和結構化報告。獲得 FDA 批准和 CE 認證的乳房攝影AI 工具正被擴大用於輔助放射科醫生,透過標記可疑觀察、優先處理複雜檢查以及減少重複的視覺搜尋任務,在確保醫生監督的前提下,實現這一目標。
北美地區在數位乳房斷層合成(DBT)技術方面仍處於成熟階段,這得益於其完善的影像基礎設施、保險覆蓋、美國食品藥品監督管理局(FDA)對醫療設備的監管、乳房密度通報政策,以及醫院網路和門診影像中心的快速普及。在歐洲,透過系統性的篩檢計畫、品質保證要求以及歐盟監管機構的嚴格審查,DBT技術正取得進展。德國、法國、義大利、西班牙和英國的國家篩檢指南和放射科容量規劃,推動了DBT技術的穩健臨床應用。
在東協地區,直接生物辨識技術(DBT)的實施主要集中在私立醫院和主要都市區,新加坡、泰國、馬來西亞、越南、菲律賓和印尼的篩檢成熟度、專家資源和資金籌措獲取情況各不相同。在海灣合作理事會(GCC)國家,由於高額醫療支出、醫療旅遊策略和對數位醫療基礎設施的投資,DBT的實施正在透過三級醫療機構、婦女健康中心和國家預防計畫加速推進。
美國憑藉著完善的保險報銷機制、FDA已通過核准的系統、對乳房密度的認知以及高密度乳房攝影網路,在數位乳房斷層合成(DBT)技術的應用方面處於領先地位。同時,加拿大正透過省級篩檢政策、醫院採購以及以品質為導向的放射學標準來擴大DBT的覆蓋範圍。在墨西哥和巴西,私人影像機構和公共癌症治療途徑對DBT的需求不斷成長,但成本效益、服務覆蓋範圍和地理可及性仍然是限制因素。
產業領導者應將數位乳房斷層合成(DBT)定位為綜合乳房健康管理流程的一部分,而非獨立的篩檢方法。商業策略應將篩檢能力、癌症檢出率、複檢管理、切片檢查整合、輻射計量最佳化、服務運轉率、放射科醫生工作流程和患者體驗等因素聯繫起來,並將其作為一項可衡量的價值提案呈現給醫療服務提供者和保險公司。
本執行摘要基於一套系統的研究方法,該方法綜合運用了同行評審的臨床文獻、監管資料庫、公共衛生指南、產品認證、採購趨勢、報銷方案更新以及專家對乳房攝影調查方法的評估。資訊來源包括權威衛生機構、醫療設備監管機構、科學期刊、臨床篩檢指南以及公開的醫院和保險公司資訊。
數位乳房斷層合成(DBT)正邁入一個更加一體化的階段,其特點是循證篩檢、人工智慧驅動的影像診斷以及全醫療機構範圍內的影像共享。儘管臨床證據持續支持其提高檢出率和降低複檢率,並推動其應用,但醫療系統也越來越重視從結果、效率、公平性、患者可及性和總體擁有成本等方面對DBT進行評估。
The Digital Breast Tomosynthesis Market is projected to grow by USD 13.77 billion at a CAGR of 15.27% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 5.09 billion |
| Estimated Year [2026] | USD 5.81 billion |
| Forecast Year [2032] | USD 13.77 billion |
| CAGR (%) | 15.27% |
Digital breast tomosynthesis (DBT), often called 3D mammography, has moved from an advanced screening option to a core breast imaging technology in many high-income health systems. The modality acquires multiple low-dose projections that are reconstructed into thin image slices, helping radiologists evaluate overlapping breast tissue more clearly than conventional 2D mammography, particularly in women with dense breast tissue.
Market momentum is grounded in clinical and operational evidence: peer-reviewed screening studies have consistently associated DBT with improved invasive cancer detection and lower recall rates compared with 2D mammography, while the WHO reported about 2.3 million new breast cancer cases and 670,000 deaths globally in 2022. These facts keep early detection, radiology capacity, reimbursement alignment, dose management, and AI-enabled workflow optimization central to the Digital Breast Tomosynthesis market.
The DBT landscape is being reshaped by the convergence of earlier screening recommendations, rising breast cancer prevalence, radiologist workforce constraints, and hospital demand for higher diagnostic confidence. In the United States, the 2024 USPSTF recommendation for biennial breast cancer screening from ages 40 to 74 reinforces broader screening access, while other clinical organizations continue to emphasize individualized risk assessment, breast density, and family history.
Manufacturers and healthcare providers are responding with lower-dose protocols, synthesized 2D imaging, faster acquisition, improved reconstruction software, contrast-enhanced mammography integration, and image-guided biopsy support. At the same time, providers are prioritizing enterprise imaging interoperability, cloud-enabled archiving, cybersecurity, regulatory compliance, and total cost of ownership, making DBT purchasing decisions increasingly strategic rather than equipment-only transactions.
Artificial intelligence is becoming a cumulative force across DBT screening, triage, lesion detection, breast density assessment, quality control, and structured reporting. FDA-cleared and CE-marked breast imaging AI tools are increasingly used to support radiologists by flagging suspicious findings, prioritizing complex exams, and reducing repetitive visual search tasks while preserving physician oversight.
The strongest near-term value proposition is operational: AI can help screening programs manage rising exam volumes without compromising standardized interpretation. Evidence from large retrospective and prospective European screening studies indicates that AI-supported workflows can reduce radiologist workload while maintaining cancer detection performance when implemented under clinical governance, validation, bias monitoring, and audit controls.
North America remains a mature DBT region, supported by accredited imaging infrastructure, payer coverage, FDA device oversight, breast density notification policies, and rapid adoption by hospital networks and outpatient imaging centers. Europe advances through organized screening programs, quality assurance requirements, and EU regulatory scrutiny, with Germany, France, Italy, Spain, and the United Kingdom contributing strong clinical adoption patterns shaped by national screening guidelines and radiology capacity planning.
Asia-Pacific is the fastest structural opportunity, driven by breast cancer burden, urban hospital investment, and expanding access in China, Japan, South Korea, Australia, and India. Latin America is led by Brazil and Mexico but remains uneven because of reimbursement gaps, public-sector procurement constraints, and regional disparities in diagnostic access. The Middle East, especially GCC markets, is investing in premium imaging centers and prevention-led women's health programs, while Africa's growth depends on infrastructure, trained radiologists, reliable service support, and affordable screening pathways.
Within ASEAN, DBT adoption is concentrated in private hospitals and major urban centers, with Singapore, Thailand, Malaysia, Vietnam, the Philippines, and Indonesia showing different levels of screening maturity, specialist availability, and capital access. GCC countries are accelerating DBT procurement through tertiary hospitals, women's health centers, and national prevention programs supported by high healthcare spending, medical tourism strategies, and investments in digital health infrastructure.
The European Union shapes global expectations through medical device regulation, organized screening quality standards, radiation dose oversight, and cross-border evidence generation. BRICS markets combine large patient populations with uneven access, making scalable procurement, service networks, workforce training, and localization essential. G7 countries remain key sources of technology innovation, reimbursement models, clinical evidence, and AI governance practices, while NATO members increasingly emphasize resilient supply chains, cybersecurity, data protection, and standardized health infrastructure for connected imaging systems.
The United States leads DBT utilization through established reimbursement, FDA-cleared systems, breast density awareness, and dense breast imaging networks, while Canada expands access through provincial screening decisions, hospital procurement, and quality-driven radiology standards. Mexico and Brazil show growing demand in private imaging and public oncology pathways, although affordability, service coverage, and geographic access remain constraints.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine screening infrastructure with evidence-based procurement, while Russia's market is influenced by domestic healthcare investment, procurement policy, and equipment availability. China is scaling advanced imaging capacity through urban hospitals and cancer centers, India is building demand through private hospitals and oncology networks, Japan and South Korea emphasize high-quality diagnostics and technology-enabled workflows, and Australia benefits from organized breast screening, strong radiology standards, and established public health awareness.
Industry leaders should position DBT as part of a complete breast health pathway rather than a standalone modality. Commercial strategies should connect screening throughput, cancer detection, recall management, biopsy integration, dose optimization, service uptime, radiologist workflow, and patient experience into a measurable value proposition for providers and payers.
Executives should prioritize evidence generation in local populations, AI validation across breast density and demographic groups, lifecycle service contracts, cybersecurity-ready connectivity, interoperability with enterprise imaging platforms, and training for technologists and radiologists. In emerging markets, success depends on flexible financing, localized service capabilities, public-private partnerships, remote support, and solutions that fit real-world screening capacity.
This executive summary reflects a structured research methodology that triangulates peer-reviewed clinical literature, regulatory databases, public health guidance, product clearances, procurement signals, reimbursement updates, and expert-level assessment of breast imaging workflows. Sources include recognized health authorities, device regulators, scientific journals, clinical screening guidance, and publicly available hospital and payer information.
Market interpretation is strengthened through segmentation by technology, end user, geography, adoption maturity, and competitive positioning. Findings are validated for consistency across clinical evidence, regulatory status, installed-base indicators, macroeconomic healthcare spending, country-level screening infrastructure, and radiology workforce dynamics to support actionable and data-backed conclusions without relying on market sizing or forecasting.
Digital breast tomosynthesis is entering a more integrated phase defined by evidence-based screening, AI-assisted interpretation, and enterprise imaging connectivity. Clinical evidence supporting improved detection and reduced recalls continues to underpin adoption, while healthcare systems increasingly evaluate DBT through outcomes, productivity, equity, patient access, and total ownership cost.
The next phase of market leadership will favor organizations that combine validated imaging performance with scalable AI, robust service networks, regulatory discipline, cybersecurity readiness, and flexible deployment models. As breast cancer screening demand grows globally, DBT will remain central to advanced breast imaging strategies across mature and emerging healthcare systems.